The leading international group in the production of pharmaceutical active ingredients Moehs, member of CATALONIA.HEALTH, has signed an exclusive agreement with EUROAPI to assume the production of Metamizol, the active ingredient of the drug Nolotil, in its facilities in Spain.
This exclusive agreement aims to complete the evaluation of the technical transfer of the production of Metamizol Magnesi and Metamizol Sodi API from the EUROAPI facilities in Frankfurt to the Moehs facilities in Spain.
Moehs reaffirms its commitment to local manufacturing in Europe, stressing the importance of ensuring a secure and solid supply chain, especially for key markets such as Spain and Germany.
Javier del Río, CEO of Moehs, highlights, “we are excited to collaborate with EUROAPI in the production of Metamizol in Spain, contributing to the manufacture and supply of medicines for European citizens with active ingredients produced in Europe. With this agreement we strengthen our position in maintaining productions in Europe to ensure supplies according to the working guides of “Medicines for Europe”.
Comments